ATE157010T1 - Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen - Google Patents

Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen

Info

Publication number
ATE157010T1
ATE157010T1 AT92913606T AT92913606T ATE157010T1 AT E157010 T1 ATE157010 T1 AT E157010T1 AT 92913606 T AT92913606 T AT 92913606T AT 92913606 T AT92913606 T AT 92913606T AT E157010 T1 ATE157010 T1 AT E157010T1
Authority
AT
Austria
Prior art keywords
amylin
anorexia
treatment
composition containing
optionally contains
Prior art date
Application number
AT92913606T
Other languages
English (en)
Inventor
Timothy J Rink
Andrew A Young
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE157010T1 publication Critical patent/ATE157010T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92913606T 1991-05-24 1992-05-23 Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen ATE157010T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70499591A 1991-05-24 1991-05-24
US86250092A 1992-04-03 1992-04-03

Publications (1)

Publication Number Publication Date
ATE157010T1 true ATE157010T1 (de) 1997-09-15

Family

ID=27107425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92913606T ATE157010T1 (de) 1991-05-24 1992-05-23 Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen

Country Status (11)

Country Link
US (1) US5656590A (de)
EP (1) EP0586589B1 (de)
JP (1) JPH06510754A (de)
AT (1) ATE157010T1 (de)
AU (1) AU669110B2 (de)
CA (1) CA2109794A1 (de)
DE (1) DE69221725T2 (de)
DK (1) DK0586589T3 (de)
ES (1) ES2108122T3 (de)
SG (1) SG49239A1 (de)
WO (1) WO1992020367A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DE69426304T2 (de) 1993-09-07 2001-03-15 Amylin Pharmaceuticals Inc Methoden zur regulation der den magen und darm betreffenden motilitaet
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US6621131B2 (en) * 2001-11-01 2003-09-16 Intel Corporation Semiconductor transistor having a stressed channel
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
EP2010208A1 (de) * 2006-03-31 2009-01-07 Amylin Pharmaceuticals, Inc. Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4992418A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
US4992417A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
GB8915712D0 (en) * 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
CA2020786A1 (en) * 1989-07-10 1991-01-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5016643A (en) * 1990-05-02 1991-05-21 Board Of Regents, The University Of Texas System Vascular entoptoscope
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
EP0586592B1 (de) * 1991-05-24 2000-11-29 Amylin Pharmaceuticals, Inc. Zusammensetzung zur Behandlung des Insulinmangels bei Säugetieren, die Amylin und Insulin enthält.

Also Published As

Publication number Publication date
DE69221725D1 (de) 1997-09-25
JPH06510754A (ja) 1994-12-01
WO1992020367A1 (en) 1992-11-26
EP0586589B1 (de) 1997-08-20
CA2109794A1 (en) 1992-11-26
US5656590A (en) 1997-08-12
DE69221725T2 (de) 1997-12-18
AU669110B2 (en) 1996-05-30
EP0586589A1 (de) 1994-03-16
SG49239A1 (en) 1998-05-18
ES2108122T3 (es) 1997-12-16
DK0586589T3 (da) 1997-09-22
AU2011592A (en) 1992-12-30

Similar Documents

Publication Publication Date Title
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE3752112D1 (de) Verwendung von Inositoltriphosphat zur Behandlung von Entzündungen
DE69410254T2 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
NO940180D0 (no) Anvendelse av IGF-I
DE69413829T2 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
ITMI931649A1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE69301750T2 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
FI925944A (fi) Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt
ATE128871T1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE69109293D1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
NO921525D0 (no) L-alfa-glyserofosforyl-d-myo-inositol for behandling av perifere nervelidelser og hjernelidelser
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie
ATE96319T1 (de) Glycyl-p-amino-pyridin zur behandlung von seniler demenz.
DE69103294T2 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
DE69218544T2 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
ATE37372T1 (de) Spiro-imidazolone fuer die behandlung von diabetischen komplikationen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee